ENDPOINTS

#ASCOGU: Lilly’s early bladder cancer data hint at safety edge over J&J’s Balversa

Eli Lilly has shared first-in-human results for its selective FGFR3 inhibitor in a subset of bladder cancer patients, marking the start of a program that could eventually challenge Johnson & Johnson’s Balversa. Balversa is marketed ...

Feb 15, 2025 - 01:02
 0
#ASCOGU: Lilly’s early bladder cancer data hint at safety edge over J&J’s Balversa
Eli Lilly has shared first-in-human results for its selective FGFR3 inhibitor in a subset of bladder cancer patients, marking the start of a program that could eventually challenge Johnson & Johnson’s Balversa. Balversa is marketed ...
Read More

Tags:

Previous Article

Buying or building a home in Australia? Here are the energy efficiency features ...

Next Article

A Flaming Flower in the Large Magellanic Cloud

Related Posts

Ascletis’ obesity pill looks similar to Roche’s drug, early data suggest

Ascletis’ obesity pill looks similar to Roche’s drug, e...

Feb 19, 2025  0

FDA approves first drug to treat ultra-rare lipid storage disease

FDA approves first drug to treat ultra-rare lipid stora...

Feb 21, 2025  0

States sue Trump administration over billions in NIH indirect cost cuts

States sue Trump administration over billions in NIH in...

Feb 10, 2025  0